Regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.

<h4>Objective</h4>Dysregulated repair following epithelial injury is a key forerunner of disease in many organs, and the acquisition of a mesenchymal phenotype by the injured epithelial cells (epithelial to mesenchymal transition, EMT) may serve as a source of fibrosis. The macrolide ant...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Balarka Banerjee, Michael Musk, Erika N Sutanto, Stephanie T Yerkovich, Peter Hopkins, Darryl A Knight, Suzanna Lindsey-Temple, Stephen M Stick, Anthony Kicic, Daniel C Chambers
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2012
Materias:
R
Q
Acceso en línea:https://doaj.org/article/6aeeacc9ffd64d5392193b4765bf2bf6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6aeeacc9ffd64d5392193b4765bf2bf6
record_format dspace
spelling oai:doaj.org-article:6aeeacc9ffd64d5392193b4765bf2bf62021-11-18T08:03:56ZRegional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.1932-620310.1371/journal.pone.0052309https://doaj.org/article/6aeeacc9ffd64d5392193b4765bf2bf62012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23284981/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>Dysregulated repair following epithelial injury is a key forerunner of disease in many organs, and the acquisition of a mesenchymal phenotype by the injured epithelial cells (epithelial to mesenchymal transition, EMT) may serve as a source of fibrosis. The macrolide antibiotic azithromycin and the DNA synthesis inhibitor mycophenolate are in clinical use but their mechanism of action remains unknown in post-transplant bronchiolitis obliterans syndrome (BOS). Here we determined if regional variation in the EMT response to TGFβ1 underlies the bronchiolocentric fibrosis leading to BOS and whether EMT could be inhibited by azithromycin or mycophenolate.<h4>Methods/results</h4>We found that small and large airway epithelial cells from stable lung transplant patients underwent EMT when stimulated with TGFβ1, however mesenchymal protein expression was higher and loss of epithelial protein expression more complete in small airway epithelial cells. This regional difference was not mediated by changes in expression of the TGFβRII or Smad3 activation. Azithromycin potentially inhibited EMT in both small and large airway epithelial cells by inhibiting Smad3 expression, but not activation.<h4>Conclusion</h4>Collectively, these observations provide a biologic basis for a previously unexplained but widely observed clinical phenomena, and a platform for the development of new approaches to fibrotic diseases.Balarka BanerjeeMichael MuskErika N SutantoStephanie T YerkovichPeter HopkinsDarryl A KnightSuzanna Lindsey-TempleStephen M StickAnthony KicicDaniel C ChambersPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 12, p e52309 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Balarka Banerjee
Michael Musk
Erika N Sutanto
Stephanie T Yerkovich
Peter Hopkins
Darryl A Knight
Suzanna Lindsey-Temple
Stephen M Stick
Anthony Kicic
Daniel C Chambers
Regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.
description <h4>Objective</h4>Dysregulated repair following epithelial injury is a key forerunner of disease in many organs, and the acquisition of a mesenchymal phenotype by the injured epithelial cells (epithelial to mesenchymal transition, EMT) may serve as a source of fibrosis. The macrolide antibiotic azithromycin and the DNA synthesis inhibitor mycophenolate are in clinical use but their mechanism of action remains unknown in post-transplant bronchiolitis obliterans syndrome (BOS). Here we determined if regional variation in the EMT response to TGFβ1 underlies the bronchiolocentric fibrosis leading to BOS and whether EMT could be inhibited by azithromycin or mycophenolate.<h4>Methods/results</h4>We found that small and large airway epithelial cells from stable lung transplant patients underwent EMT when stimulated with TGFβ1, however mesenchymal protein expression was higher and loss of epithelial protein expression more complete in small airway epithelial cells. This regional difference was not mediated by changes in expression of the TGFβRII or Smad3 activation. Azithromycin potentially inhibited EMT in both small and large airway epithelial cells by inhibiting Smad3 expression, but not activation.<h4>Conclusion</h4>Collectively, these observations provide a biologic basis for a previously unexplained but widely observed clinical phenomena, and a platform for the development of new approaches to fibrotic diseases.
format article
author Balarka Banerjee
Michael Musk
Erika N Sutanto
Stephanie T Yerkovich
Peter Hopkins
Darryl A Knight
Suzanna Lindsey-Temple
Stephen M Stick
Anthony Kicic
Daniel C Chambers
author_facet Balarka Banerjee
Michael Musk
Erika N Sutanto
Stephanie T Yerkovich
Peter Hopkins
Darryl A Knight
Suzanna Lindsey-Temple
Stephen M Stick
Anthony Kicic
Daniel C Chambers
author_sort Balarka Banerjee
title Regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.
title_short Regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.
title_full Regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.
title_fullStr Regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.
title_full_unstemmed Regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.
title_sort regional differences in susceptibiity of bronchial epithelium to mesenchymal transition and inhibition by the macrolide antibiotic azithromycin.
publisher Public Library of Science (PLoS)
publishDate 2012
url https://doaj.org/article/6aeeacc9ffd64d5392193b4765bf2bf6
work_keys_str_mv AT balarkabanerjee regionaldifferencesinsusceptibiityofbronchialepitheliumtomesenchymaltransitionandinhibitionbythemacrolideantibioticazithromycin
AT michaelmusk regionaldifferencesinsusceptibiityofbronchialepitheliumtomesenchymaltransitionandinhibitionbythemacrolideantibioticazithromycin
AT erikansutanto regionaldifferencesinsusceptibiityofbronchialepitheliumtomesenchymaltransitionandinhibitionbythemacrolideantibioticazithromycin
AT stephanietyerkovich regionaldifferencesinsusceptibiityofbronchialepitheliumtomesenchymaltransitionandinhibitionbythemacrolideantibioticazithromycin
AT peterhopkins regionaldifferencesinsusceptibiityofbronchialepitheliumtomesenchymaltransitionandinhibitionbythemacrolideantibioticazithromycin
AT darrylaknight regionaldifferencesinsusceptibiityofbronchialepitheliumtomesenchymaltransitionandinhibitionbythemacrolideantibioticazithromycin
AT suzannalindseytemple regionaldifferencesinsusceptibiityofbronchialepitheliumtomesenchymaltransitionandinhibitionbythemacrolideantibioticazithromycin
AT stephenmstick regionaldifferencesinsusceptibiityofbronchialepitheliumtomesenchymaltransitionandinhibitionbythemacrolideantibioticazithromycin
AT anthonykicic regionaldifferencesinsusceptibiityofbronchialepitheliumtomesenchymaltransitionandinhibitionbythemacrolideantibioticazithromycin
AT danielcchambers regionaldifferencesinsusceptibiityofbronchialepitheliumtomesenchymaltransitionandinhibitionbythemacrolideantibioticazithromycin
_version_ 1718422290963628032